Healthcare · Drug Manufacturers - General
Latest call day: 2026-10-23 · full consensus board · graded history
Price (daily close, 2026-10-23)
Trailing returns (daily closes)
Today's calls AI
| Biotech · Low Volatility | UP 100% | Low Volatility — the low-volatility anomaly. GILD ranks #1 of 8 in Biotech (100% bullish percentile, annualized volatility 26%), so the agent calls it UP for the next session. |
| Biotech · Donchian | UP 71% | Donchian — position within the Donchian channel. GILD ranks #3 of 8 in Biotech (71% bullish percentile), so the agent calls it UP for the next session. |
| Biotech · Momentum | UP 71% | Momentum — trailing return (trend-following). GILD ranks #3 of 8 in Biotech (71% bullish percentile, signal +5.0%), so the agent calls it UP for the next session. |
| Biotech · MACD | UP 43% | MACD — MACD histogram momentum crossover. GILD ranks #5 of 8 in Biotech (43% bullish percentile), so the agent calls it UP for the next session. |
| Biotech · Volume Thrust | UP 29% | Volume Thrust — volume-confirmed accumulation. GILD ranks #6 of 8 in Biotech (29% bullish percentile), so the agent calls it UP for the next session. |
| Biotech · Momentum Acceleration | UP 14% | Momentum Acceleration — trend speeding up. GILD ranks #7 of 8 in Biotech (14% bullish percentile, signal +8.6%), so the agent calls it UP for the next session. |
Best agents on GILD (graded record)
| Biotech · LightGBM | 73% | 32/44 correct | DOWN |
| Biotech · Mean-Reversion | 65% | 20/31 correct | UP |
| Biotech · 52-Week-High | 61% | 14/23 correct | UP |
| Biotech · SOTA Ensemble | 61% | 20/33 correct | DOWN |
| Biotech · Low Volatility | 60% | 28/47 correct | UP |
| Biotech · Momentum Acceleration | 58% | 48/83 correct | UP |
| Biotech · MACD | 57% | 48/84 correct | UP |
| Biotech · Momentum | 57% | 48/84 correct | UP |
| Biotech · Donchian | 57% | 42/74 correct | UP |
| Biotech · Regime Switch | 56% | 9/16 correct | DOWN |
Recent news
| 2026-10-24 | Gilead Sciences (GILD) Could Be 22% Overvalued Following Its Liver Meeting Update · yf_tkr_GILD |
| 2026-10-24 | Stocktwits Biotech Dealmaker: Gilead And Roche Double Down On Early-Stage Assets Over Full Buyouts This Week · yf_tkr_GILD |
| 2026-10-23 | Firm Advises PepStar Therapeutics on Patent Matters Related to Acquisition of Inflammation Drug Program by Gilead Sciences · Wilson Sonsini |
| 2026-10-23 | The Lanier Law Firm Supports Attorney General Ken Paxton in Reaching $45 Million Settlement with Gilead in Unlawful Inducement Scheme · yf_tkr_GILD |
| 2026-10-23 | Gilead spends $1.28bn on PepStar’s potential Icotyde rival · yf_tkr_GILD |
| 2026-10-23 | 3 Defensive Stocks to Buy as the AI Selloff Rattles Wall Street · yf_tkr_GILD |
How grading works: every call is locked before the open and scored on the session's open→close move — see the methodology.
Open Fortivio.AI →Model-generated predictions with a live graded record — not investment advice. 模型生成的预测，非投资建议。